Article
Oncology
Haiyan Zhang, Zhiping Fan, Fen Huang, Lijie Han, Yajing Xu, Na Xu, Lan Deng, Shunqing Wang, Dongjun Lin, Xiaodan Luo, Qing Zhang, Xiaodan Liu, Xudong Li, Xinquan Liang, Shuangfeng Xie, Hong Qu, Sijian Yu, Hongsheng Zhou, Pengcheng Shi, Li Xuan, Ren Lin, Hui Liu, Hua Jin, Jing Sun, Qifa Liu
Summary: A randomized phase III trial in China compared busulfan plus cyclophosphamide (BuCy) regimen with total body irradiation plus cyclophosphamide (TBI-Cy) regimen as conditioning for allo-HSCT in adult standard-risk B-cell-ALL patients. The study found that BuCy regimen had noninferior efficacy and safety compared to TBI-Cy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yuan-Yuan Shi, Zeng-Yan Liu, Gui-Xin Zhang, Yi He, Ming-Zhe Han, Si-Zhou Feng, Rong-Li Zhang, Er-Lie Jiang
Summary: This study explores the safety and effectiveness of a cladribine-based conditioning regimen for autologous hematopoietic stem cell transplantation in patients with acute myeloid leukemia. The results indicate that this regimen is a successful and safe approach for AML treatment.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Baohang Zhang, Qingguo Liu, Junfan Li, Yimin Hu, Xin Zhao, Pingping Huang, Shangzhu Li, Ying Wang
Summary: In this study, a shortened 3-day cyclophosphamide and Ara-C regimen was used, with the addition of low-dose venetoclax (VEN), and the efficacy and safety were reported. The results showed that this regimen is highly effective in newly diagnosed AML patients and the addition of VEN achieves a higher and deeper one-course remission.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biophysics
Jaime Sanz, Myriam Labopin, Thomas Pabst, Jurjen Versluis, Gwendolyn Van Gorkom, Ellen Meijer, Tobias Gedde-Dahl, Juan Montoro, William Arcese, Jose Antonio Perez-Simon, Nicolaas Schaap, Johan Maertens, Radovan Vrhovac, Francesco Lanza, Norbert Claude Gorin, Mohamad Mohty, Fabio Ciceri
Summary: We compared the impact of different conditioning regimens, including BEA, BUCY, and BUMEL, on the outcomes of adult AML patients in CR1 undergoing ASCT. The BEA regimen showed better overall survival compared to BUCY and BUMEL. This retrospective study suggests that the high-dose myeloablative combination chemotherapy with BEA is a more effective treatment option for AML patients in CR1.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Ziying Li, Wei Shi, Xuan Lu, Hui Lu, Xiena Cao, Liang Tang, Han Yan, Zhaodong Zhong, Yong You, Linghui Xia, Yu Hu, Huafang Wang
Summary: This study found that decitabine-intensified myeloablative conditioning could reduce the incidence of acute graft-versus-host disease and improve the overall survival and GVHD-free relapse-free survival in patients with acute myeloid leukemia after related donor hematopoietic stem cell transplantation.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Claire Seydoux, Michael Medinger, Sabine Gerull, Joerg Halter, Dominik Heim, Yves Chalandon, Stavroula Masouridi Levrat, Urs Schanz, Gayathri Nair, Marc Ansari, Patrick Simon, Jakob R. Passweg, Nathan Cantoni
Summary: Reversing the order of application of cyclophosphamide and busulfan in myeloablative conditioning for allo-HCT patients may lead to better outcomes. Short-term results show advantages of CyBu over BuCy in terms of liver toxicity, while long-term follow-up demonstrates lower non-relapse mortality and higher survival with CyBu compared to BuCy.
ANNALS OF HEMATOLOGY
(2021)
Article
Biophysics
Eleni Gavriilaki, Myriam Labopin, Ioanna Sakellari, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Victoria Potter, Ana Berceanu, Alessandro Rambaldi, Inken Hilgendorf, Nicolaus Kroeger, Stephan Mielke, Tsila Zuckerman, Jaime Sanz, Alessandro Busca, Hakan Ozdogu, Achilles Anagnostopoulos, Bipin Savani, Sebastian Giebel, Ali Bazarbachi, Alexandros Spyridonidis, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of treosulfan plus fludarabine and busulfan in different patient groups, and found that busulfan had better outcomes in younger patients.
BONE MARROW TRANSPLANTATION
(2022)
Article
Medicine, General & Internal
Shiyuan Zhou, Yingying Zhai, Lingzhi Yan, Xiaolan Shi, Jingjing Shang, Depei Wu, Chengcheng Fu, Song Jin
Summary: The dose-adjusted busulfan/cyclophosphamide regimen may be an alternative treatment option for autologous stem cell transplantation in patients with multiple myeloma and has shown promising efficacy.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Emanuele Angelucci, Mutlu Arat, Mahmoud Aljurf, Simona Sica, Jiri Pavlu, Gerard Socie, Paolo Bernasconi, Luigi Rigacci, Johanna Tischer, Antonio Risitano, Montserrat Rovira, Riccardo Saccardi, Pietro Pioltelli, Gwendolyn Van Gorkom, Antonin Vitek, Bipin N. Savani, Alexandros Spyridonidis, Zinaida Peric, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of two conditioning regimens for adult acute lymphoblastic leukemia patients undergoing haploidentical hematopoietic cell transplantation. The results showed that the use of fludarabine + total body irradiation (Flu-TBI) reduced the risk of non-relapse mortality, while the use of thiotepa + iv. busulfan + fludarabine (TBF) may reduce the risk of relapse.
BONE MARROW TRANSPLANTATION
(2022)
Article
Biophysics
Sebastian Giebel, Myriam Labopin, Malgorzata Sobczyk-Kruszelnicka, Matthias Stelljes, Jenny L. Byrne, Nathalie Fegueux, Dietrich W. Beelen, Montserrat Rovira, Alexandros Spyridonidis, Didier Blaise, Martin Bornhaeuser, Ihsan Karadogan, Bipin N. Savani, Arnon Nagler, Mohamad Mohty, Sonja Martin, Patrice Chevallier, Andreas Neubauer, Gandhi Damaj, Yener Koc, Arnold Ganser, Matthew Collin, Ibrahim Yakoub-Agha, Hakan Ozdogu, Mercedes Colorado Araujo, Maija Itala-Remes, Kim Orchard, Cecilia Isaksson, Wolfgang Bethge, Hans Martin, Mahmoud Aljurf, Edgar Faber, Dolores Caballero, Pavel Zak, Xavier Leleu, Jacques-Olivier Bay, Pierre-Simon Rohrlich, Nicolaus Kroeger, Anne Huynh, Kerstin Schaefer-Eckart, Noel Milpied, Stig Lenhoff, Aloysius Ho, Jose Luis Bello Lopez, Nicola Mordini, Bruno Lioure, Kazimierz Halaburda, Attilio Olivieri, Tobias Gedde-Dahl, Rachel Protheroe, Johanna Tischer, Matthias Klammer, Johannes Clausen, Victoria Potter, Marco Ladetto, Herve Tilly, Eric Deconinck, Arne Brecht, Lutz Peter Mueller, Thomas Heinicke, Juan Pio Torres Carrete, Ali Bazarbachi, Peter Remenyi, Marie Therese Rubio, Renato Fanin, Jose Antonio Perez-Simon, Murawski Niels, J. L. Diez-Martin, Mutlu Arat, Olivier Hermine, Gerard Socie, Jan J. Cornelissen, Stella Santarone, Denis Guyotat, Claude Eric Bulabois, Paolo Bernasconi, Jan-Erik Johansson, Radovan Vrhovac, Hildegard Greinix, Jose Luis Lopez Lorenzo, Shashikant Apte, Charles Craddock, Guido Kobbe, Mohsen Al Zahrani, Peter Dreger, Andrzej Lange, Abdelghani Tbakhi, Ellen Meijer, Carlos Vallejo Llamas, Josep Maria Ribera Santasusana, Paolo Corradini, Fabio Benedetti, Alessandro Rambaldi, Virginie Gandemer, Jean-Valere Malfuson, Ain Kaare, Antonio Risitano, Mario Petrini, Carmine Selleri, Depei Wu
Summary: This study suggests that the use of TBI8Gy/Flu as a reduced-toxicity regimen may be beneficial for younger patients with AML undergoing allo-HCT. Conversely, older patients using TBI8Gy/Flu were associated with increased NRM incidence.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Mari Morita-Fujita, Yasuyuki Arai, Tadakazu Kondo, Kaito Harada, Naoyuki Uchida, Takashi Toya, Yukiyasu Ozawa, Takahiro Fukuda, Shuichi Ota, Makoto Onizuka, Yoshinobu Kanda, Yumiko Maruyama, Satoru Takada, Toshiro Kawakita, Takahide Ara, Tatsuo Ichinohe, Takafumi Kimura, Yoshiko Atsuta, Shinichi Kako
Summary: The VP16/CY/TBI regimen showed better progression-free survival and reduced relapse rate in adult Ph+ ALL patients undergoing myeloablative allo-HSCT compared to the CY/TBI regimen. However, it did not significantly improve outcomes in Ph- ALL patients.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Oncology
Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).
Article
Biophysics
Shuhei Kurosawa, Yoshimitsu Shimomura, Hidehiro Itonaga, Yuho Najima, Takeshi Kobayashi, Yukiyasu Ozawa, Yoshinobu Kanda, Shinichi Kako, Toshiro Kawakita, Ken-ichi Matsuoka, Yumiko Maruyama, Shuichi Ota, Hideyuki Nakazawa, Kazunori Imada, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Jun Aoki
Summary: Myeloablative conditioning with Fludarabine/Busulfan (Flu/Bu4) and busulfan/cyclophosphamide (Bu4/Cy) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed similar outcomes in MDS patients, with no patients having a favorable overall survival rate in either group.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
A. Birgitta Versluijs, Coco C. H. de Koning, Arjan C. Lankester, Stefan Nierkens, Wouter J. Kollen, Dorine Bresters, Caroline A. Lindemans, Jaap Jan Boelens, Marc Bierings
Summary: This study prospectively investigated the use of clofarabine-fludarabine-busulfan (CloFluBu) conditioning in allogeneic hematopoietic cell therapy, showing limited toxicity and encouraging event-free survival (EFS). The median age of all patients was approximately 9.7 years, with a 2-year EFS of 72.0% in acute lymphoid leukemia patients and 62.4% in acute myeloid leukemia patients.
Article
Biophysics
Anne Banet, Ali Bazarbachi, Myriam Labopin, Nicolas Stocker, Remy Dulery, Florent Malard, Zoe Van de Wyngaert, Alexis Genthon, Mara Memoli, Ollivier Legrand, Agnes Bonnin, Tounes Ledraa, Ramdane Belhocine, Simona Sestili, Jean El-Cheikh, Mohamad Mohty, Eolia Brissot
Summary: Total body irradiation (TBI)-based conditioning regimens are commonly used in acute lymphoblastic leukemia (ALL) patients, but studies have shown comparable outcomes with thiotepa-based conditioning regimen. In this retrospective study, we evaluated the outcome of adult ALL patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with a thiotepa-busulfan-fludarabine (TBF) myeloablative conditioning regimen. The results showed promising overall survival and acceptable toxicity in these patients.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Anais Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, Titouan Cazaubiel, Marie-Lorraine Chretien, Philippe Moreau, Thierry Facon, Xavier Leleu, Lionel Karlin, Anne-Marie Stoppa, Olivier Decaux, Karim Belhadj, Bertrand Arnulf, Mohamad Mohty, Clara Mariette, Cecile Fohrer-Sonntag, Pascal Lenain, Jean-Pierre Marolleau, Mourad Tiab, Carla Araujo, Frederique Orsini-Piocelle, Arnaud Jaccard, Murielle Roussel, Lotfi Benboubker, Jean-Richard Eveillard, Mamoun Dib, Marion Divoux, Michel Attal, Herve Avet-Loiseau, Jill Corre
Summary: In the era of personalized treatment in multiple myeloma, accurately identifying high-risk patients is crucial. The Revised International Staging System (R-ISS) is recommended for this purpose. This study aims to explore the heterogeneity of outcome among R-ISS stage II patients and assess the impact of ISS stage, chromosomal abnormalities, and lactate dehydrogenase level in this subgroup.
Letter
Hematology
Michele Wieczorek, Myriam Labopin, Luca Castagna, Eolia Brissot, Gerard Socie, Anna Maria Raiola, Emanuele Angelucci, Arancha Bermudez Rodriguez, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Charles Crawley, Jean Baptiste Mear, Maurizio Musso, Renato Fanin, Daniele Avenoso, Pascal Turlure, Cristina Tecchio, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biophysics
Mohamad Mohty, Didier Blaise, Regis Peffault de Latour, Myriam Labopin, Jean Henri Bourhis, Benedicte Bruno, Patrice Ceballos, Marie Detrait, Virginie Gandemer, Anne Huynh, Faezeh Izadifar-Legrand, Charlotte Jubert, Helene Labussiere-Wallet, Delphine Lebon, Sebastien Maury, Catherine Paillard, Cecile Pochon, Cecile Renard, Fanny Rialland, Pascale Schneider, Anne Sirvent, Kobby Asubonteng, Gwennaelle Guindeuil, Ibrahim Yakoub-Agha, Jean-Hugues Dalle
Summary: This study evaluated the effectiveness and safety of defibrotide in patients undergoing haematopoietic cell transplantation (HCT). The results showed that defibrotide had a good effect in treating severe/very severe VOD/SOS, with high survival and complete response rates.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Sebastian Giebel, Myriam Labopin, Gerard Socie, Mahmoud Aljurf, Urpu Salmenniemi, Helene Labussiere-Wallet, Micha Srour, Nicolaus Kroeger, Mohsen Al Zahrani, Bruno Lioure, Peter Remenyi, Mutlu Arat, Jean Henri Bourhis, Grzegorz Helbig, Abdelghani Tbakhi, Edouard Forcade, Anne Huynh, Eolia Brissot, Alexandros Spirydonidis, Bipin N. Savani, Zinaida Peric, Arnon Nagler, Mohamad Mohty
Summary: This registry-based study compared the outcomes of allo-HCT for adult ALL patients using TBI combined with either Cy or Flu as conditioning. TBI/Cy was associated with a reduced risk of relapse and increased risk of acute GVHD compared to TBI/Flu. Matched-pair analysis showed that TBI/Cy had a significantly lower relapse rate without significant effects on non-relapse mortality, GVHD, and survival, suggesting it as a preferable regimen for ALL patients in remission.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot, Remy Dulery, Joel Gozlan, Anne Daguenel, Yasmine Abi Aad, Laure Ricard, Nicolas Stocker, Anne Banet, Agnes Bonnin, Tamim Alsuliman, Zora Marjanovic, Aurelie Schnuriger, Paul Coppo, Ollivier Legrand, Karine Lacombe, Mohamad Mohty, Florent Malard
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Marie Robin, Luuk Gras, Linda Koster, Riccardo Saccardi, Juergen Finke, Edouard Forcade, Montserrat Rovira, Guido Kobbe, Peter Remenyi, Jane Apperley, Arghirescu Smaranda, Jacques-Olivier Bay, Jochen Casper, Liesbeth. C. C. de Wreede, Sebastian Giebel, Giovanni Grillo, Inmaculada Heras, Victoria Potter, Johanna Tischer, Ilze Trociukas, David Nachbaur, Joanna Drozd-Sokolowska, Kavita Raj, Carmelo Gurnari, Ibrahim Yakoub-Agha, Francesco Onida, Christof Scheid, Donal McLornan
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Ibrahim Yakoub-Agha, Raffaella Greco, Francesco Onida, Rafael de la Camara, Fabio Ciceri, Selim Corbacioglu, Harry Dolstra, Bertram Glass, Michelle Kenyon, Donal P. McLornan, Benedicte Neven, Regis Peffault de Latour, Zinaida Peric, Annalisa Ruggeri, John A. Snowden, Anna Sureda, Isabel Sanchez-Ortega
Summary: Clinical patient care for hematopoietic cell transplantation and cellular therapy varies between countries and centers. To harmonize clinical practices, European guidelines will be developed by the EBMT PH&G committee through workshops with experts. These guidelines aim to provide clear and practical recommendations in the absence of international consensus.
BONE MARROW TRANSPLANTATION
(2023)
Review
Biophysics
Mohamad Mohty, Florent Malard, Ahmed S. Alaskar, Mahmoud Aljurf, Mutlu Arat, Peter Bader, Frederic Baron, Ali Bazarbachi, Didier Blaise, Eolia Brissot, Fabio Ciceri, Selim Corbacioglu, Jean-Hugues Dalle, Fiona Dignan, Anne Huynh, Michelle Kenyon, Arnon Nagler, Antonio Pagliuca, Zinaida Peric, Paul G. Richardson, Annalisa Ruggeri, Tapani Ruutu, Ibrahim Yakoub-Agha, Rafael F. Duarte, Enric Carreras
Summary: Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can occur after hematopoietic cell transplantation (HCT). The European Society for Blood and Marrow Transplantation (EBMT) has recently updated the definition and severity grading system for SOS/VOD in adult patients. The aim of this work is to provide an update on the diagnosis, severity assessment, pathophysiology, and treatment of SOS/VOD in adult patients.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
David Michonneau, Nadia Quignot, Heng Jiang, Dawn Reichenbach, Maebh Kelly, Anita Burrell, Xiang Zhang, Kris Thiruvillakkat, Mohamad Mohty
Summary: This study comprehensively investigates the clinical and economic burden of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation in France. The results demonstrate that patients with GVHD have a higher risk of severe infection, higher mortality rates, higher hospital admission rates, and higher direct costs compared to patients without GVHD.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty
Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Philipp Berning, Norbert Schmitz, Maud Ngoya, Herve Finel, Ariane Boumendil, Fengrong Wang, Xiao-Jun Huang, Olivier Hermine, Laure Philippe, Lucile Couronne, Arnaud Jaccard, Daihong Liu, Depei Wu, Hans Christian Reinhardt, Yves Chalandon, Eva Wagner-Drouet, Mi Kwon, Xi Zhang, Ben Carpenter, Ibrahim Yakoub-Agha, Gerald Wulf, Javier Lopez-Jimenez, Jaime Sanz, Helene Labussiere-Wallet, Avichai Shimoni, Peter Dreger, Anna Sureda, Won Seog Kim, Bertram Glass
Summary: In this study, researchers conducted a retrospective analysis of data from 135 patients with natural killer/T-cell lymphomas (NKTCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). The results showed that allo-HSCT can achieve long-term survival in NKTCL patients.
Article
Biophysics
Tapani Ruutu, Christophe Peczynski, Mohamed Houhou, Emmanuelle Polge, Mohamad Mohty, Nicolaus Kroeger, Ivan Moiseev, Olaf Penack, Nina Salooja, Helene Schoemans, Rafael F. Duarte, Thomas Schroeder, Jakob Passweg, Gerald G. Wulf, Arnold Ganser, Simona Sica, Mutlu Arat, Urpu Salmenniemi, Annoek E. C. Broers, Jean Henri Bourhis, Alessandro Rambaldi, Johan Maertens, Kazimierz Halaburda, Tsila Zuckerman, Helene Labussiere-Wallet, Grzegorz Basak, Christian Koenecke, Zinaida Peric
Summary: The study investigated the incidence, diagnostic policy, management, and outcome of VOD/SOS at EBMT centers. It included 71 participating centers with a total of 2886 allogeneic transplantations and 93 cases of VOD/SOS in 2018. The findings showed a low incidence of VOD/SOS and a predominance of severe and very severe grades, indicating the importance of early diagnosis and treatment to improve outcomes.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Kai Rejeski, Raffaella Greco, Francesco Onida, Isabel Sanchez-Ortega, Chiara Bonini, Anna Sureda, John G. Gribben, Ibrahim Yakoub-Agha, Marion Subklewe
Summary: The pathophysiology of hematological toxicity after CAR-T cell therapy is not fully understood and its grading and management are not well-defined. This study conducted a survey of experienced clinicians to gather insights on the grading, risk-stratification, diagnostic work-up, and management of immune effector cell-associated hematotoxicity (ICAHT) in order to inform guideline development. The survey revealed significant variability in cytopenia grading, a preference for pre-CAR-T bone marrow studies in high-risk patients, and a need for ruling out viral infections, substrate deficiency, and coincident sHLH/MAS in patients with severe hematotoxicity.
Review
Immunology
Camille N. Kotton, Julian Torre-Cisneros, Ibrahim Yakoub-Agha, CMV Int Symposium Fac
Summary: This article reviews the presentations, cases, and discussions from the 2023 International CMV Symposium, discussing the challenges of managing cytomegalovirus infection after transplantation and the opportunities to improve transplant recipients' outcomes.
TRANSPLANT INFECTIOUS DISEASE
(2023)
